ForSight VISION5 Finds $15M

Menlo Park-based Forsight VISION5, a developer of ocular inserts for treating glaucoma, dry eye, and allergy, said yesterday that it has raised $15M in a Series C funding round. The funding came from H.I.G. BioVentures, as well as Morgenthaler Ventures, Versant Ventures, Technology Partners, and Delphi Ventures. More information »